Capricor Therapeutics (CAPR) Accumulated Expenses (2010 - 2026)

Capricor Therapeutics' Accumulated Expenses history runs 11 years deep, the most recent figure standing at $10.5 million for Q1 2026.

• In Q1 2026, Accumulated Expenses rose 148.24% year-over-year to $10.5 million; the TTM figure through Mar 2026 stood at $10.5 million (up 148.24% YoY), while the FY2025 annual figure was $15.6 million, up 509.5% from the prior year.
• Accumulated Expenses was $10.5 million for Q1 2026 at Capricor Therapeutics, down from $15.6 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $15.6 million in Q4 2025 to a low of $2.6 million in Q4 2024.
• Historically, Accumulated Expenses has averaged $7.8 million across 3 years, with a median of $7.1 million in 2025.
• The sharpest annual moves came in 2025 and 2026: Accumulated Expenses jumped 509.5% in 2025, then jumped 148.24% in 2026.
• A 3-year view of Accumulated Expenses shows it stood at $2.6 million in 2024, then surged by 509.5% to $15.6 million in 2025, then plunged by 32.33% to $10.5 million in 2026.
• The last three Accumulated Expenses figures came in at $10.5 million (Q1 2026), $15.6 million (Q4 2025), and $9.9 million (Q3 2025), per Business Quant data.